Tirzepatide vs Mounjaro — the difference between a compound and its brand names. Mounjaro and Zepbound are tirzepatide; what research-grade tirzepatide is and isn't. Research use only.
"Tirzepatide vs Mounjaro" is a common search, and the short answer is that they are not two different compounds. Mounjaro is a brand name for tirzepatide. This explains the compound-versus-brand distinction and what research-grade tirzepatide is. It is research/educational information only, not medical advice. For the compound and formats, see the Tirzepatide hub.
Tirzepatide is the molecule. Mounjaro and Zepbound are brand names under which that same molecule is marketed as a prescription medicine. So "tirzepatide vs Mounjaro" is really "the compound vs one of its brands" — not two different drugs.
The material sold here is research-grade tirzepatide, supplied strictly for laboratory research use. It is not the branded pharmaceutical, is not dispensed as a prescription, and is not for human use. The compound is the same; the regulatory status, formulation, and intended use are not.
Tirzepatide is a dual agonist, engaging both the GLP-1 and GIP receptors. That places it between the single agonist semaglutide (GLP-1) and the triple agonist retatrutide (GLP-1/GIP/glucagon). The GLP-1 receptor agonists comparison covers the differences.
Is tirzepatide the same as Mounjaro? Yes, as a molecule. Mounjaro (and Zepbound) are brand names under which tirzepatide is marketed as a prescription medicine.
Is research-grade tirzepatide the same as Mounjaro? It is the same compound but not the same product: research-grade tirzepatide is supplied for laboratory research use only, not as the branded pharmaceutical and not for human use.
How is tirzepatide different from semaglutide? Tirzepatide is a dual GLP-1/GIP agonist; semaglutide is a single GLP-1 agonist.
Is this medical advice? No. Tirzepatide here is supplied for research use only; nothing on this page is medical advice.
